159 related articles for article (PubMed ID: 10210394)
1. Clinical efficacy and safety of tolterodine compared to placebo in detrusor overactivity.
Millard R; Tuttle J; Moore K; Susset J; Clarke B; Dwyer P; Davis BE
J Urol; 1999 May; 161(5):1551-5. PubMed ID: 10210394
[TBL] [Abstract][Full Text] [Related]
2. Tolterodine treatment for children with symptoms of urinary urge incontinence suggestive of detrusor overactivity: results from 2 randomized, placebo controlled trials.
Nijman RJ; Borgstein NG; Ellsworth P; Djurhuus JC
J Urol; 2005 Apr; 173(4):1334-9. PubMed ID: 15758796
[TBL] [Abstract][Full Text] [Related]
3. Treatment of urge-predominant mixed urinary incontinence with tolterodine extended release: a randomized, placebo-controlled trial.
Khullar V; Hill S; Laval KU; Schiøtz HA; Jonas U; Versi E
Urology; 2004 Aug; 64(2):269-74; discussion 274-5. PubMed ID: 15302476
[TBL] [Abstract][Full Text] [Related]
4. Tolterodine: superior tolerability than and comparable efficacy to oxybutynin in individuals 50 years old or older with overactive bladder: a randomized controlled trial.
Malone-Lee J; Shaffu B; Anand C; Powell C
J Urol; 2001 May; 165(5):1452-6. PubMed ID: 11342895
[TBL] [Abstract][Full Text] [Related]
5. Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head-to-head placebo-controlled trial.
Herschorn S; Swift S; Guan Z; Carlsson M; Morrow JD; Brodsky M; Gong J
BJU Int; 2010 Jan; 105(1):58-66. PubMed ID: 20132103
[TBL] [Abstract][Full Text] [Related]
6. A randomized double-blind placebo-controlled multicentre study to explore the efficacy and safety of tamsulosin and tolterodine in women with overactive bladder syndrome.
Robinson D; Cardozo L; Terpstra G; Bolodeoku J;
BJU Int; 2007 Oct; 100(4):840-5. PubMed ID: 17822465
[TBL] [Abstract][Full Text] [Related]
7. Propiverine versus tolterodine: efficacy and tolerability in patients with overactive bladder.
Jünemann KP; Halaska M; Rittstein T; Mürtz G; Schnabel F; Brünjes R; Nurkiewicz W
Eur Urol; 2005 Sep; 48(3):478-82. PubMed ID: 15967567
[TBL] [Abstract][Full Text] [Related]
8. Comparison of fesoterodine and tolterodine in patients with overactive bladder.
Chapple CR; Van Kerrebroeck PE; Jünemann KP; Wang JT; Brodsky M
BJU Int; 2008 Nov; 102(9):1128-32. PubMed ID: 18647298
[TBL] [Abstract][Full Text] [Related]
9. Does urodynamic verification of overactive bladder determine treatment success? Results from a randomized placebo-controlled study.
Malone-Lee JG; Al-Buheissi S
BJU Int; 2009 Apr; 103(7):931-7. PubMed ID: 19281469
[TBL] [Abstract][Full Text] [Related]
10. Safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction.
Abrams P; Kaplan S; De Koning Gans HJ; Millard R
J Urol; 2006 Mar; 175(3 Pt 1):999-1004; discussion 1004. PubMed ID: 16469601
[TBL] [Abstract][Full Text] [Related]
11. Long-term safety, tolerability and efficacy of extended-release tolterodine in the treatment of overactive bladder in Japanese patients.
Takei M; Homma Y;
Int J Urol; 2005 May; 12(5):456-64. PubMed ID: 15948744
[TBL] [Abstract][Full Text] [Related]
12. Extended-release tolterodine with or without tamsulosin in men with lower urinary tract symptoms and overactive bladder: effects on urinary symptoms assessed by the International Prostate Symptom Score.
Kaplan SA; Roehrborn CG; Chancellor M; Carlsson M; Bavendam T; Guan Z
BJU Int; 2008 Nov; 102(9):1133-9. PubMed ID: 18510659
[TBL] [Abstract][Full Text] [Related]
13. A new once-daily formulation of tolterodine provides superior efficacy and is well tolerated in women with overactive bladder.
Swift S; Garely A; Dimpfl T; Payne C;
Int Urogynecol J Pelvic Floor Dysfunct; 2003 Feb; 14(1):50-4; discussion 54-5. PubMed ID: 12601517
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and tolerability of tolterodine extended-release in men with overactive bladder and urgency urinary incontinence.
Roehrborn CG; Abrams P; Rovner ES; Kaplan SA; Herschorn S; Guan Z
BJU Int; 2006 May; 97(5):1003-6. PubMed ID: 16643482
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the efficacy of tolterodine and oxybutynin in different urodynamic severity grades of idiopathic detrusor overactivity.
Giannitsas K; Perimenis P; Athanasopoulos A; Gyftopoulos K; Nikiforidis G; Barbalias G
Eur Urol; 2004 Dec; 46(6):776-82; discussion 782-3. PubMed ID: 15548447
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of solifenacin in patients previously treated with tolterodine extended release 4 mg: results of a 12-week, multicenter, open-label, flexible-dose study.
Chancellor MB; Zinner N; Whitmore K; Kobashi K; Snyder JA; Siami P; Karram M; Laramée C; Capo' JP; Seifeldin R; Forero-Schwanhaeuser S; Nandy I
Clin Ther; 2008 Oct; 30(10):1766-81. PubMed ID: 19014833
[TBL] [Abstract][Full Text] [Related]
17. A multicenter, double-blind, randomized, placebo controlled trial of a neurokinin-1 receptor antagonist for overactive bladder.
Frenkl TL; Zhu H; Reiss T; Seltzer O; Rosenberg E; Green S
J Urol; 2010 Aug; 184(2):616-22. PubMed ID: 20639026
[TBL] [Abstract][Full Text] [Related]
18. The clinical efficacy of tolterodine extended-release is maintained for 24 h in patients with overactive bladder.
Dmochowski R; Kreder K; MacDiarmid S; Carlsson M; Guan Z
BJU Int; 2007 Jul; 100(1):107-10. PubMed ID: 17552957
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and tolerability of tolterodine extended-release in continent patients with overactive bladder and nocturia.
Nitti VW; Dmochowski R; Appell RA; Wang JT; Bavendam T; Guan Z;
BJU Int; 2006 Jun; 97(6):1262-6. PubMed ID: 16686723
[TBL] [Abstract][Full Text] [Related]
20. Randomized trial of percutaneous tibial nerve stimulation versus extended-release tolterodine: results from the overactive bladder innovative therapy trial.
Peters KM; Macdiarmid SA; Wooldridge LS; Leong FC; Shobeiri SA; Rovner ES; Siegel SW; Tate SB; Jarnagin BK; Rosenblatt PL; Feagins BA
J Urol; 2009 Sep; 182(3):1055-61. PubMed ID: 19616802
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
